HONG KONG – Chinese biotech firm Origimed Co. Ltd., of Shanghai, is taking part in building China's first cancer big data platform with two oncology organizations to gather genetic data of the Chinese population. That will give doctors more precise information to diagnose cancer and customize treatment.